Mentor Capital Cancer Immunotherapy Index Gains 29% During First Half of 2012
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary
Cancer Immunotherapy Index has appreciated 28.7% during the first half
of 2012. The equally weighted Cancer Immunotherapy Index is regularly
benchmarked against the appreciation of the average of the NASDAQ, S&P,
and NYSE Biotech Indices. For the first half the biotech indices
averaged a 30.7% gain. In comparison, during the first six months of
2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.42%,
8.31% and 12.66%, respectively.
Immunocellular Therapeutics (176%), Agenus (162%) and Celldex (99%) have
led the sector in gains during the January thru June 2012 period. Cancer
immunotherapy pioneer, Dendreon, dominates the market capitalization of
the sector, representing 49% of the combined Cancer Immunotherapy Index
total share value of $2.3 Billion.
The Mentor Capital Cancer Immunotherapy Index companies and their
reported first half 2012 gains follow: Dendreon (NASDAQ:DNDN) -2.63%,
Immunocellular Therapeutics, Ltd. (AMEX:IMUC) +175.74%, Agenus
(NASDAQ:AGEN) +162.00%, Oncothyreon (NASDAQ:ONTY) -38.26%, Biovest
International (BVTI.PK) +9.33%, Celldex Therapeutics (NASDAQ:CLDX)
+99.04%, Northwest Biotherapeutics (OTCBB:NWBO) -36.46%, CEL – SCI Corp.
(AMEX:CVM) +31.08% , Generex Biotechnology (OTCBB:GNBT) -38.67% as a
proxy for its wholly-owned immunotherapeutic subsidiary, Antigen
Express, Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) +3.70% and
Advaxis, Inc. (OTCBB:ADXS) -42.02% - all for an average six month gain
of +28.72% (approximately +57.44% if annualized).
Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest
in leading-edge private and public cancer companies and those associated
companies that reduce the cost of medical treatments. Mentor created the
Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or
maintained a tracking position in all companies in the Cancer
Immunotherapy Index. The Index company summaries can be tracked through
updates of the Cancer Immunotherapy Index presented at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are
Incorporated by Reference from the MNTR Company Web Site above.
Mentor Capital, Inc. Chester Billingsley, CEO 760-788-4700